XBiotech Inc

XBITNASDAQUSD
2.28 USD
0.02 (0.89%)AT CLOSE (11:59 AM EDT)
2.29
0.01 (0.22%)
POST MARKET (AS OF 07:34 PM EDT)
Post Market
AS OF 07:34 PM EDT
2.29
0.01 (0.22%)
🔴Market: CLOSED

Shares of XBiotech Inc (XBIT) are trading at $2.27. Our models show a "Sell" technical signal alongside a "Neutral" fundamental rating. Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On the valuation side, XBIT appears attractively valued relative to sector peers across key multiples.

Technical & fundamental data as of Aug 6, 2026.

Open?$2.28
High?$2.28
Low?$2.26
Prev. Close?$2.26
Volume?10.0K
Avg. Volume?38.6K
VWAP?$2.27
Rel. Volume?0.26x
Bid / Ask
Bid?$1.91 × 100
Ask?$2.60 × 100
Spread?$0.69
Midpoint?$2.26
Valuation & Ratios
Market Cap?68.9M
Shares Out?30.5M
Float?16.7M
Float %?54.8%
P/E Ratio?N/A
P/B Ratio?0.51
EPS?-$1.32
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
Employees
87
Market Cap
68.9M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2015-04-15
Address
5217 WINNEBAGO LANE
AUSTIN, TX 78744
Phone: 512-386-2900
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bearish(-2/3)
Medium-Term (Wave)? Neutral(0/3)
Short-Term (Ripple)? Bullish(+2/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
50
Short Sent.?
71
Piotroski F-Score?0/9Weak
Altman Z-Score?6.99Safe
Confidence?40%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?1.69%Low
Short Interest?281.5K
Days to Cover?7.2
Free Float16.7M
Avg Daily Volume39.0K
Settlement Date2026-07-15
Financial Health
Current Ratio?39.03Strong
Quick Ratio?39.03Strong
Cash Ratio?38.50Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A
P/B?
Peers
100
S&P
97
0.51CHEAP
P/S?
N/A
P/FCF?
N/A
EV/EBITDA?
Peers
100
S&P
97
1.0CHEAP
EV/Sales?
N/A
Returns & Efficiency
ROE?
S&P
6
-29.8%WEAK
ROA?
S&P
3
-28.7%WEAK
Cash Flow & Enterprise
FCF?$-42364000
Enterprise Value?$-46556728
Fundamentals ratios updated end of day